secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2023-04-28T23:59:59+00:00
Accession:  0001193125-23-124510
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest reports positive early Phase 1b/2 data for TPST-1120 in HCC; ORR improved vs control
--------------------------------------------------------------------------------

- Unconfirmed ORR 30% (12/40) for TPST-1120 arm vs 17.2% (5/29) control, a 74.4% relative improvement.
- Confirmed ORR 17.5% (7/40) vs 10.3% (3/29) control, a 69.9% relative improvement.
- 47.5% (19/40) of TPST-1120 arm patients remain on treatment vs 23.3% (7/30) in control arm.
- 80% (32/40) in TPST-1120 arm on study vs 50% (15/30) control; safety consistent with control.
- Secondary endpoints (DoR, PFS, OS) immature; full data expected at a medical meeting later.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312523124510/0001193125-23-124510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312523124510/d479206d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-124510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer